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Background and objective: Superficial venous surgery for CEAP 2 disease leads to an improvement in disease-specific
quality of life (QoL) in the short term. However, which factors influence the magnitude of this improvement, how
surgery affects QoL in patients with CEAP 4 to 6 disease, and whether this improvement is durable are not known. The
objective of this study was to identify patient, operative, and surgeon factors that might influence the change in
disease-specific QoL in the 2 years after superficial venous surgery.
Methods: This prospective study was comprised of 203 unselected, consecutive patients with CEAP 2 to 6 disease who
underwent saphenous with or without subfascial endoscopic perforator surgery and who completed the Aberdeen
Varicose Vein Symptoms Severity Score (AVVSSS) before surgery and at 4 weeks, 6 months, and 2 years after surgery.
Univariate and multivariate analyses were performed.
Results: At baseline, recurrent and ulcer (CEAP 5 and 6) diseases were associated with a higher (worse) AVVSSS. Surgery
was associated with a significant improvement in median (interquartile range [IQR]) AVVSSS: baseline, 17.8 (11.8 to
27.2); 4 weeks, 13.8 (7.9 to 21.3); 6 months, 9.6 (4.2 to 15.8); and 2 years, 8.1 (4.0 to 14.7). One hundred seventy-five
patients (86%) at 6 months and 177 patients (87%) at 2 years reported an improvement in AVVSSS. Postoperative
AVVSSS at both 6 months and 2 years was most significantly influenced by preoperative score (P < .0001). After
adjustment for baseline AVVSSS, the following factors were identified in multivariate analysis as having a significant and
independent positive () or negative () impact on AVVSSS: at 6 months, () recurrent disease (P  .009), () CEAP
4 disease (P  .026); and at 2 years, () long saphenous surgery (P  .02), () CEAP 5 disease (P  .030).
Conclusion: In this unselected series, saphenous surgery with or without subfascial endoscopic perforator surgery led to
an improvement in disease-specific QoL in 87% of patients out to 2 years. Although univariate analysis results suggested
that many baseline factors might be associated with outcome, multivariate analysis results suggested that only surgery for
recurrent disease and for CEAP 4/5 disease remained as significant negative, and only long saphenous surgery as
significant positive, independent prognostic factors. These data provide evidence of the medium-term clinical effective-
ness of venous surgery across the full spectrum of CEAP clinical grades, show the importance of multivariate analysis, and
reemphasize the importance of minimization of recurrence. (J Vasc Surg 2002;36:896-902.)
In the United Kingdom, approximately 80,000 vari-
cose vein (VV) operations are performed each year, with
about two thirds in the publicly funded National Health
Service (NHS) and one third in the private sector. The
indications for surgery vary widely from predominantly
cosmetic concerns to intractable chronic venous ulcer.
Overall, approximately 80% of patients undergo long sa-
phenous vein (LSV) surgery alone, 10% short saphenous
vein (SSV) surgery alone, and 10% both. Around 20% of
operations are performed for recurrent disease.1 In recent
years, a waxing and waning of enthusiasm has been seen for
subfascial endoscopic perforator surgery (SEPS), and the
indications for the procedure remain controversial.2
Three major problems bedevil venous surgery in the
United Kingdom. First, VV surgery has become the most
common cause of medicolegal action against general and
vascular surgeons in this traditionally nonlitigious coun-
try.3 The causes for suit are broad, ranging from major
vascular injury (the minority) to concerns about the cos-
metic appearance of the leg, unresolved symptomatology,
and recurrence (the majority). Second, it is now clear that a
poor relationship exists between so-called venous symp-
toms, signs of venous disease on clinical examination,4 and
objective evidence of reflux on duplex ultrasonography.5
And third, to date, proving that VV surgery with or without
SEPS confers adjuvant benefit over best medical therapy for
ulcer (CEAP 5/6) disease has not been possible.6
These three factors, together with the non-life-threat-
ening nature of the condition, have inevitably led to pres-
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sure on United Kingdom vascular surgeons not to perform
venous surgery within an increasingly underresourced
NHS.7 Although this may lead to increased activity in the
private sector in the short term, generally insurers will not
continue to pay for treatment that is no longer provided by
the NHS because of the assumption that such treatment is
ineffective. It must also be remembered that only about 5%
of United Kingdom citizens have private health insurance.
Although individuals can, and increasingly do, decide to
pay for their own treatment, it is apparent that those most
in need are often those least able to pay.
To prove that venous surgery is worthwhile and worth
reimbursement in the public and private sectors, an urgent
need to prove that it is clinically effective exists. This can be
done through observational studies,8,9 registries such as the
North American Subfascial Endoscopic Perforator Sur-
gery,6 and, of course, randomized controlled trials.10
However, because patients who undergo venous surgery
are so heterogeneous, a decision on the most appropriate
endpoints can be difficult. The traditional measure of suc-
cess, surgical morbidity and mortality, is insufficient. Clin-
ical endpoints might include recurrence (persistence) of
VV, clinically11 or on duplex ultrasound scan,12 or ulcer
healing and recurrence.13 However, increasingly it is being
appreciated that the patient perception of what constitutes
benefit is the most important measure of success.14 This
can be determined through the application of patient satis-
faction surveys,15 venous severity scoring,16 or formally
validated generic and disease-specific quality of life (QoL)
instruments.17,18
For these reasons, groups, including ourselves, have
attempted to quantify the clinical and cost effectiveness of
venous surgery with QoL instruments.19 Unfortunately, to
date, venous surgery has not been shown to be associated
with particularly impressive changes in generic QoL as
measured with the SF-36, for example.20 Attention has
therefore turned to disease-specific instruments,21,22 which
may be more sensitive to clinically meaningful changes in
QoL among patients who undergo this type of surgery.
Simple saphenous surgery for uncomplicated (CEAP
clinical grade 2) disease has previously been shown to lead
to a significant reduction (improvement) in the Aberdeen
Varicose Vein Symptom Severity Score (AVVSSS) at 6
weeks after surgery.17 However, longer term data were not
available and patients with recurrent VV, deep venous
disease, or CEAP 4 to 6 disease were specifically excluded.
As such, the situation with regard to patients with more
advanced disease, and in the longer term, is unclear. Fur-
thermore, it is apparent that many patient-dependent, sur-
gery-dependent, and operator-dependent factors might in-
fluence whether or not, and to what degree, venous surgery
does indeed lead to a meaningful improvement in symp-
toms and thus QoL. As with any other condition, the
surgeon must be aware of the factors that influence prog-
nosis when taking informed consent. The aim of this study,
therefore, is to determine which factors influence outcome
after venous surgery out to 2 years after surgery.
METHODS
This was a prospective study of 203 consecutive, uns-
elected patients who underwent LSV or SSV or SEPS
surgery for CEAP 2 (symptomatic VV) to 6 (open ulcer-
ation) disease and who completed the AVVSSS before
surgery and at 4 weeks, 6 months, and 2 years after surgery.
A reduction in the AVVSSS relates to an improved QoL.
Operative techniques and perioperative care have been
described previously.19 Preoperative imaging, duplex ultra-
sonography in all cases, was performed at the discretion of
the individual surgeon. Scans were mainly requested for
patients with CEAP 5/6, recurrent, and short saphenous
disease. LSV surgery comprised flush saphenofemoral junc-
tion ligation, stripping of the LSV in the thigh, and multi-
ple stab avulsions, and SSV surgery comprised saphenopo-
pliteal junction ligation and multiple stab avulsions. The
SSV was not stripped in any patient. SEPS was performed
with a single port technique, without gas insufflation, with
tourniquet control with clipping of perforators. Patients
were provided with thromboembolic deterrent stockings
on the first postoperative day and were advised to wear
them for 2 weeks. Patients with CEAP 4 to 6 disease were
subsequently fitted with classification II below-knee com-
pressions stockings.
Baseline information was collected at the time of ad-
mission to the hospital for surgery (Table I) and included
age, gender, preoperative AVVSSS, type of surgery, CEAP
clinical grade, whether the procedure was for primary (no
previous surgery on that leg or saphenous territory) or
recurrent disease (second operation on the same leg in the
same saphenous territory), and whether a history of deep
Table I. Baseline data entered into models
Baseline factor No.
Patient characteristics
Age (y) 19 to 84 (mean, 55.6; standard
error, 0.89)
Male/female 67 (33%)/136 (67%)
DVT history 7 (3%)
ABPI  0.8 5 (3%)
CEAP clinical grade
2/3 62 (31%)
4 93 (46%)
5 23 (11%)
6 25 (12%)
Type of surgery
Unilateral/bilateral 158 (78%)/45 (22%)
Primary/recurrent disease 124 (61%)/79 (39%)
LSV only 135 (67%)
SSV only 17 (8%)
LSV and SSV 35 (18%)
SEPS 15 (6 LSV, 2 SSV, 6 LSV and SSV)
Grade of primary operator
Consultant 54 (27%)
Registrar 91 (45%)
Senior House Officer 58 (29%)
Primary surgery is defined as first operation of that leg in that saphenous
distribution. Recurrent surgery is defined as second operation on same leg in
same saphenous distribution.
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vein thrombosis (DVT) or evidence of arterial insufficiency
(resting ankle:brachial pressure index [ABPI] of 0.8)
existed. The grade of the primary operator was also col-
lected. Grade of surgeon was considered as a continuous
variable. Consultant equated with attending, specialist reg-
istrar with senior resident or fellow, and senior house officer
with junior resident or intern. In patients who underwent
bilateral surgery, the baseline factors entered into the sta-
tistical analysis were those of the “worst” leg. However,
that the AVVSSS assesses the impact that both legs have on
patient overall perception of health is important to note.
Postoperative QoL data were gathered with distribution
and collection of completed QoL questionnaires by mail.
Linear regression, with the dependent variables being
the AVVSSS at 6 months and at 2 years, was used to
determine which of the baseline factors significantly af-
fected postoperative AVVSSS. This was done as an unad-
justed analysis and with adjustment for baseline AVVSSS.
Analyses were completed on the square root of the AVVSSS
as they were not normally distributed and normality could
not be assumed for the residuals when completing the
linear regression on the untransformed variables. The
square root was chosen rather than the natural logarithm
because the AVVSSS could and did take the score of zero in
some cases. R2 gives the proportion of variability of the
score that the model can explain; the higher the value of R2,
the better the fit of the model.
RESULTS
Overall effect of surgery on quality of life. In com-
parison with baseline AVVSSS, a significant reduction (im-
provement) was seen in AVVSSS at 6 months and 2 years
(both Wilcoxon signed rank test, P  .001) but not at 4
weeks (Wilcoxon signed rank test, P  .44; Table II). At 6
months, 175 patients (86%) had an improved (lower)
AVVSSS, one patient (0.5%) showed no change, and 27
patients (13.5%) had a worse (higher) AVVSSS. At 2 years,
the numbers (proportions) of patients with improvement,
no change, and deterioration were 177 (87%), 1 (0.5%),
and 25 (13%), respectively. No significant difference was
found between 6 months and 2 years in the proportion of
patients deriving benefit or the magnitude of that benefit. A
highly significant correlation was seen between baseline
AVVSSS and the improvement in AVVSSS between base-
line and 2 years. This was true for the cohort as a whole (r
0.62; P  .0001; Fig 1) and for CEAP grades 2/3 (r 
0.53; P  .001), 4 (r  0.6; P  .001), 5 (r  0.61; P 
.02), and 6 (r  0.80; P  .0001) when considered
separately.
Patients who underwent surgery for recurrent disease
(n  124) had significantly higher (worse) AVVSSS at
baseline, 4 weeks, 6 months (P  .001, Mann-Whitney
test), and 2 years (P  .005; Fig 2). Patients who under-
went surgery for complicated disease also had worse AV-
VSSS (Fig 3). No significant difference was seen in AVVSSS
at any time point between patients who underwent unilat-
eral or bilateral (n  45; 22%) surgery (data not shown).
Consultants operated personally on 54 patients (27%) and
supervised trainees in operations on 28 patients (14%).
Trainees performed unsupervised operations on 121 pa-
tients (59%). Patients who underwent operation by con-
sultants were more likely to have recurrent and advanced
(CEAP 5/6) disease than those who underwent operation
by trainees.
Univariate analysis of baseline factors that affect
Aberdeen Varicose Vein Symptoms Severity Score at 6
months. A higher baseline AVVSSS, surgery for recurrent
disease, the presence of CEAP 4 to 6 disease, an ABPI of
less than 0.8, and a more experienced primary operator all
predicted a higher (worse) AVVSSS at 6 months (Table
III). However, after adjustment for baseline AVVSSS, only
surgery for recurrent disease, skin changes (CEAP 4), and a
more experienced surgeon remained significant negative
prognostic predictors.
That the AVVSSS at 6 months is influenced by age,
with older patients having a higher score (P  .054; R2 
0.135), has been suggested. However, a statistically signif-
icant but weak correlation was seen between age and the
square root of baseline AVVSSS (Pearson correlation coef-
ficient: r  0.215; P  .002), and the influence of age
disappeared once the analysis had been adjusted for base-
line AVVSSS. This is also the case for CEAP 6 disease
(Pearson correlation coefficient: r  0.426; P  .003),
which explains why the strong relationship between active
ulceration and high postoperative AVVSSS at 6 months
(P  .002) disappears once the data are adjusted for base-
line AVVSSS. A similar situation pertains for arterial insuf-
ficiency and a history of DVT.
Patients who underwent operation by consultants had
the highest AVVSSS at 6 months, and this remains the case
Table II. Preoperative and postoperative AVVSSS
AVVSSS score Mean
Standard
error Median Quartiles Range
Before surgery 20.2 0.80 17.7 11.8, 27.2 3.3, 70.8
A  4 weeks 16.0 0.75 13.8 7.9, 21.3 0.0, 51.9
A  6 months 11.8 0.71 9.6 4.2, 15.8 0.0, 56.8
A  2 years 10.2 0.63 8.1 4.0, 14.7 0.0, 52.2
Change between baseline and 6 months 8.4 0.73 7.5 13.3, 3.0 66.8, 29.9
Change between baseline and 2 years 10.1 0.84 8.8 15.1, 3.4 66.8, 24.0
Reduction in AVVSSS denotes improvement in disease-specific Q.L.
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even after adjustment for baseline AVVSSS. However, after
adjustment for all other baseline factors in a multivariate
analysis (see subsequent), no significant difference was seen
between different grades of surgeon. Therefore, as might
be expected, the higher AVVSSS for consultant operations
appears to be the result of operating on patients with less
favorable conditions. The models explain only 10% to 20%
of the total variation in the square root of the AVVSSS at 6
months but more than 50% once baseline AVVSSS has been
taken into account.
Fig 1. Relationship between AVVSSS at baseline and 2 years after surgery. Patients represented with points on line
reported no change in disease-specific QoL between baseline and 2 years after surgery. Patients below line reported
benefit, and those above line reported deterioration.
Fig 2. Median AVVSSS in patients who underwent venous sur-
gery for primary and recurrent disease. Significance difference at
baseline, 4 weeks, and 6 months, P  .001. At 2 years, P  .005,
with Mann-Whitney U test.
Fig 3. Median AVVSSS in patients who underwent venous sur-
gery for CEAP 2/3, 4, 5, and 6 disease.
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Univariate analysis of baseline factors that affect
Aberdeen Varicose Vein Symptoms Severity Score at 2
years. Eight baseline factors were associated with a signif-
icantly higher AVVSSS at 2 years: namely, a higher baseline
AVVSSS, increasing age, recurrent disease, CEAP 4 or 5
disease, a history of DVT, performance of SEPS, and a
more experienced primary operator. The performance of
LSV surgery alone was associated with a significantly lower
AVVSSS at 2 years. That the outcome at 2 years was best in
patents who underwent LSV surgery alone and worst in
those who underwent SEPS almost certainly reflects the
fact that SEPS was only performed for patients with com-
plicated (CEAP 4 to 6) disease.
After adjustment for baseline AVVSSS, only the pres-
ence of CEAP 5 disease and LSV surgery remained as
significant negative and positive predictors, respectively, of
outcome at 2 years (Table IV). Weak but statistically sig-
nificant relationships were seen between baseline AVVSSS
and surgery for recurrent disease (Pearson correlation
coefficient: r  0.206; P  .003), CEAP 4 disease (r 
0.355; P  .000), ABPI less than 0.8 (r  0.174; P 
.013), and grade of surgeon (r  0.152; P  .031).
This may explain in part why these factors influence the
AVVSSS at 2 years singly but do not when baseline
AVVSSS is taken into account. The models explain be-
tween 10% and 15% of the total variation in AVVSSS at 2
years but between 40% and 45% once baseline AVVSSS
has been taken into account.
It is apparent from the univariate analysis that factors
that predict AVVSSS at 6 months and 2 years are not the
same. Specifically, surgery for recurrent disease is an adverse
factor with respect to 6-month but not 2-year outcome.
The reasons for this are not entirely clear but may relate to
increased surgical morbidity and recovery time. Further-
more, the type of surgery performed does not appear to
affect outcome at 6 months but does at 2 years. This
suggests that some types of surgery may have a more
durable beneficial effect than others.
Table III. Effects of baseline factors on AVVSSS at 6 months: univariate analysis
Factor
Unadjusted Adjusted for square root of baseline AVVSSS
Coefficient
Standard
error P value R2 Coefficient
Standard
error P value R2
Square root of baseline AVVSSS 0.66 0.07 .000 0.56
Gender 0.20 0.21 .348 0.07 0.02 0.18 .916 0.56
Age 0.02 0.01 .054 0.14 0.02 0.01 .809 0.56
Primary or recurrent procedure 0.75 0.20 .000 0.26 0.43 0.17 .013 0.58
CEAP 6 0.92 0.29 .002 0.22 0.11 0.27 .692 0.57
CEAP 5 0.70 0.30 .021 0.16 0.48 0.25 .055 0.58
CEAP 4 0.90 0.19 .000 0.32 0.37 0.18 .036 0.58
History of DVT 0.95 0.54 .083 0.12 0.50 0.46 .274 0.57
ABPI  0.8 1.92 0.63 .003 0.21 1.05 0.54 .052 0.58
Grade of surgeon 0.43 0.13 .001 0.23 0.28 0.11 .012 0.58
LSV surgery 0.48 0.33 .149 0.10 0.24 0.28 .385 0.57
SSV surgery 0.31 0.22 .154 0.10 0.12 0.18 .498 0.57
SEPS 0.50 0.38 .192 0.09 0.21 0.32 .511 0.57
Table IV. Effects of baseline factors on AVVSSS at 2 years: univariate analysis
Factor
Unadjusted Adjusted for square root of baseline AVVSSS
Coefficient
Standard
error P value R2 Coefficient
Standard
error P value R2
Square root of baseline AVVSSS 0.50 0.08 .000 0.42
Gender 0.27 0.22 .224 0.09 0.13 0.20 .517 0.42
Age 0.02 0.01 .029 0.15 0.01 0.01 .310 0.42
Primary or recurrent procedure 0.51 0.21 .016 0.17 0.26 0.20 .184 0.42
CEAP 6 0.29 0.30 .351 0.07 0.59 0.31 .056 0.43
CEAP 5 0.86 0.31 .006 0.19 0.70 0.28 .015 0.44
CEAP 4 0.67 0.20 .001 0.23 0.27 0.20 .179 0.42
History of DVT 1.13 0.56 .047 0.14 0.79 0.52 .130 0.43
ABPI  0.8 1.16 0.66 .081 0.12 0.50 0.62 .422 0.42
Grade of surgeon 0.30 0.13 .027 0.16 0.18 0.13 .145 0.43
LSV surgery 1.00 0.34 .004 0.20 0.82 0.31 .010 0.45
SSV surgery 0.17 0.23 .458 0.05 0.02 0.21 .906 0.42
SEPS 0.88 0.39 .026 0.16 0.66 0.36 .067 0.43
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Multivariate analysis of baseline factors that affect
Aberdeen Varicose Vein Symptoms Severity Score at 6
months and at 2 years. After adjustment for baseline
AVVSSS, recurrent disease and CEAP 4 disease predicted
higher AVVSSS at 6 months (Table V). The model ex-
plained 60% of the total variation in AVVSSS at 6 months.
At 2 years after surgery, CEAP 5 disease predicted a higher
AVVSSS and the performance of LSV surgery predicted a
lower AVVSSS after adjustment for baseline AVVSSS (Ta-
ble VI). The model explained 47% of the total variation in
the square root of the AVVSSS at 2 years.
DISCUSSION
The principal finding of this study is that the great
majority (86% at 6 months and 87% at 2 years) of patients
who undergo superficial venous surgery gain a significant
and durable improvement in disease-specific QoL. Further-
more, the worse the symptoms (higher the AVVSSS) at
baseline, the greater the improvement in symptoms be-
tween baseline and 2 years. This confirms and extends the
results of a previous study in which the AVVSSS was used to
assess the results of surgery at 6 weeks. In that study,
patients with recurrent VV, deep venous disease, skin
changes, or an ulcer history were specifically excluded.17 In
this study, all patients who underwent saphenous surgery
with or without SEPS were included. This perhaps explains
why the baseline AVVSSS in this study was higher. How-
ever, the reduction in AVVSS seen between baseline and 4
weeks in the study by Smith et al17 is remarkably similar to
that found between baseline and 6 weeks in this study.
In addition to extending the knowledge base to a wider
group of patients, this study also provides medium-term
follow-up data. Overall, about 40% of the improvement is
present as early as 6 weeks after surgery, another 50% occurs
between 4 weeks and 6 months, and the remaining 10%
accrues between 6 months and 2 years. However, it is
important to note that considerable variation exists be-
tween patients both in terms of the absolute and percentage
improvement and in its timing and durability. Indeed, the
primary reason for this prospective, multivariate analysis
was the desire to understand better the relationship be-
tween the medium-term response to surgery and the wide
range of clinical, operative, and surgeon variables at base-
line.
The considerable clinical heterogeneity of patients who
undergo superficial venous surgery in our unit is reflected in
the 20-fold variation in preoperative AVVSSS. Not surpris-
ingly, patients with advanced venous (CEAP 4 to 6) disease
tended to have worse (higher) preoperative AVVSSS than
those with simple VV (CEAP 2). Furthermore, patients
with recurrent disease also tended to have a worse preop-
erative disease-specific QoL. However, within each CEAP
group, there was again considerable variation in AVVSSS.
The need to treat each patient as an individual is
reemphasized with these data that show that preoperative
QoL (AVVSSS) has by far the largest effect on postopera-
tive improvement. In other words, those patients with the
least symptoms have the least to gain from surgery and
those with the worst symptoms have the most to gain. It is
also worth specifically pointing out that preoperative AV-
VSSS has a greater effect on postoperative AVVSSS than
CEAP grade. Thus, in terms of disease-specific QoL, a
highly symptomatic patient with simple VV (CEAP 2) may
have as much, if not more, to gain (relatively) from surgery
than a less symptomatic patient with complicated venous
disease (CEAP 4 to 6). For this reason, the univariate
analyses have been performed before and after adjustment
for preoperative AVVSSS, and in the multivariate analysis,
baseline AVVSSS was the first variable to be entered into
the stepwise model.
As might be expected, univeriate analysis has indenti-
fied a large number of baseline variables that appear to
impact outcome. Surgery for recurrent disease, advanced
clinical grade (CEAP 4 to 6), history of DVT, and presence
of arterial disease (ABPI  0.8) are all associated with a
higher AVVSSS at 6 months and 2 years after surgery.
However, as discussed previously, many of these factors are
related to baseline AVVSSS, and when postoperative AV-
VSSS is adjusted for baseline score, many of these relation-
ships are no longer significant.
Table V. Effects of baseline factors on AVVSSS at 6 months: multivariate analysis
Factor Parameter estimate Standard error t P value
Intercept 0.11 0.35 0.33 .742
Square root of baseline AVVSSS 0.57 0.07 7.78 .000
Primary/recurrent procedure 0.45 0.17 0.15 .009
CEAP 4 0.39 0.17 0.14 .026
Table VI. Effects of baseline factors on AVVSSS at 2 years: multivariate analysis
Factor Parameter estimate Standard error t P value
Intercept 1.37 0.46 2.96 .003
Square root of baseline AVVSSS 0.47 0.08 6.16 .000
LSV surgery 0.73 0.31 2.35 .020
CEAP 5 0.62 0.28 2.19 .030
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It is apparent from the univariate analysis that factors
that predict AVVSSS at 6 months and 2 years may not be
the same. Specifically, surgery for recurrent disease is an
adverse factor with respect to 6-month but not 2-year
outcome. The reasons for this are not entirely clear, but the
data do suggest that this may relate to increased surgical
morbidity and recovery time in patients who undergo op-
eration for recurrent disease. Furthermore, the type of
surgery performed does not appear to affect outcome at 6
months but does at 2 years. This may suggest that some
types of surgery may have a more pronounced and durable
beneficial effect than others. However, because the type of
surgery performed depends on the nature of the presenting
disease, this is a complex area that requires further study. In
this study, the small number of patients who underwent
SEPS did not appear to fare particularly well. However, in
our practice, SEPS is usually only performed in patients
with CEAP 5 and 6 disease and then mainly in patients who
have demonstrable deep venous insufficiency.
The interdependence of patient, operative, and surgeon
factors is clearly shown with the results of the multivariate
analysis. Failure to undertake such an analysis, especially when
considering such a heterogenous group of patients, may lead
to erroneous conclusions being drawn. For example, the
unadjusted univariate analysis showed that patients who un-
derwent operation by a consultant appeared to have a worse
outcome than those who underwent operation by a surgical
trainee. Even when data were adjusted for baseline AV-
VSSS, this remained the case at 6 months. However, sur-
geon grade, along with several other baseline variables,
disappeared with multivariate analysis. In other words, con-
sultants appeared to have worse results because they were
operating on the patients with least favorable conditions.
In summary, in the great majority of patients, superfi-
cial venous surgery with or without SEPS has a highly
significant positive effect on disease-specific QoL as mea-
sured with the AVVSSS out to 2 years. The magnitude of
the improvement is most powerfully influenced by the
severity of the preoperative score; those with the worst
symptoms gain the most improvement. Trainees, when
appropriately supervised, appear to get results as good as
consultants. Although patients who undergo LSV surgery
for primary VV may gain a more durable benefit than
patients who undergo SEPS or saphenous surgery for re-
current disease, the latter still gain a significant improve-
ment in QoL in most cases. In conclusion, these data
provide strong evidence of the medium-term clinical effec-
tiveness of superficial venous surgery across the full spec-
trum of CEAP clinical grades, show the importance of
multivariate analysis, and reemphasize the importance of
minimizing recurrence.
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